EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Sleep-related breathing disorders in patients with pulmonary hypertension



Sleep-related breathing disorders in patients with pulmonary hypertension



Chest 133(6): 1375-1380



Background: The airways in patients with cystic fibrosis (CF) are characterized by the accumulation of tenacious, dehydrated mucus that is a precursor for chronic infection, inflammation, and tissue destruction. The clearance of mucus is an integral component of daily therapy. inhaled mannitol is an osmotic agent that increases the water content of the airway surface liquid, and improves the clearance of mucus with the potential to improve lung function and respiratory health. To this end, this study examined the efficacy and safety of therapy with inhaled mannitol over a 2-week period.Methods; This was a randomized, double-blind, placebo-controlled, crossover study. Thirty-nine subjects with mild-to-moderate CF lung disease inhaled 420 mg of mannitol or placebo twice daily for 2 weeks. Following a 2-week washout period, subjects were entered in the reciprocal treatment arm. Lung function, respiratory symptoms, quality of life, and safety were assessed.Results: Mannitol treatment increased FEV1 from baseline by a mean of 7.0% (95% confidence interval [CI], 3.3 to 10.7) compared to placebo 0.3% (95% CI, - 3.4 to 4.0; p < 0.001). The absolute improvement with mannitol therapy was 121 mL (95% CI, 56.3 to 185.7), which was significantly more than that with placebo (0 mL; 95% CI, - 64.7 to 64.7). The forced expiratory flow in the middle half of the FVC increased by 15.5% (95% CI, - 6.5 to 24.6) compared to that with placebo (increase, 0.7%; 95% CI, - 8.3 to 9.7; p < 0.02). The safety profile of mannitol was adequate, and no serious adverse events related to treatment were observed.Conclusions: inhaled mannitol treatment over a period of 2 weeks significantly improved lung function in patients with CF. Mannitol therapy was safe and well tolerated.Trial registration: Clinical Trials.gov Identifier: NCT00455130.

(PDF emailed within 0-6 h: $19.90)

Accession: 033411389

Download citation: RISBibTeXText

PMID: 18339776

DOI: 10.1378/chest.07-3035



Related references

Pulmonary hypertension and sleep-related breathing disorders. Pneumologie 59(4): 270-274, 2005

Etiopathogenetic mechanisms of pulmonary hypertension in sleep-related breathing disorders. Pulmonary Medicine 2012: 273591-273591, 2012

Sleep-related breathing disorders recorded by an ambulatory system in patients with chronic pulmonary and thoracal disorders. Tubercle & Lung Disease 75(SUPPL 1): 136, 1994

Sleep-related breathing disorders in patients with idiopathic pulmonary fibrosis. Lung 185(3): 173-178, 2007

Gender differences in pulmonary function among patients with sleep related breathing disorders. European Respiratory Journal 8(SUPPL 19): 211S, 1995

Guidelines for diagnosis and treatment of sleep-related breathing disorders in adults and children. Definition and classification of sleep related breathing disorders in adults: different types and indications for sleep studies (Part 1). Hippokratia 13(3): 187-191, 2009

Does placebo treatment lower nocturnal blood pressure in patients with sleep-related breathing disorders and arterial hypertension?. Cardiology 82(SUPPL 1): 69-78, 1993

Sleep Related Breathing Disorders and Inflammation - The Missing Link? A Cohort Study Evaluating the Interaction of Inflammation and Sleep Related Breathing Disorders and Effects of Treatment. Plos One 10(9): E0137594-E0137594, 2016

Effects of continuous positive airway pressure therapy on hypertension control in patients with sleep-related breathing disorders: available evidence and unresolved issues. Journal of Hypertension 28(10): 2012-2015, 2011

Gender-related differences in symptoms of patients with suspected breathing disorders in sleep: a clinical population study using the sleep disorders questionnaire. Sleep 30(3): 312-319, 2007

Effect of sertraline on breathing in depressed patients without moderate-to-severe sleep-related breathing disorders. Sleep & Breathing 19(4): 1377-1386, 2015

Effect of sertraline on breathing in depressed patients without moderate-to-severe sleep related breathing disorders. Sleep Medicine 16: S173-S174, 2015

Oral breathing in patients with sleep-related breathing disorders. Acta Oto-Laryngologica 122(6): 651-654, 2002

Sleep-related breathing disorders as a major cause of essential hypertension: fact or fiction?. Current Opinion in Nephrology and Hypertension 7(4): 353-357, 1998

Sleep apnea and sleep-related breathing disorders in patients with craniofacial synostosis. Acta Oto-Laryngologica. Supplementum 517: 6-10, 1994